Top Banner
Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath Hospital Johannesburg, South Africa
18

Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Dec 27, 2015

Download

Documents

Jean Floyd
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Care and Prevention in HIV Vaccine Trials: a site perspective

Guy de Bruyn

Perinatal HIV Research UnitUniversity of the Witwatersrand

Chris Hani Baragwanath HospitalJohannesburg, South Africa

Page 2: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Access to care (modified from Grady)

• Care which is part of the scientific design

• Care needed to safely complete the trial

• Care for injuries and adverse events

• Post trial access

• Ancillary care– Care that some participants will

predictably need

Page 3: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Dialogue?

• “a comprehensive care package should be agreed upon through a host/community/sponsor dialogue which reaches consensus prior to initiation of a trial” (UNAIDS 2000, #16)…

Page 4: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Protocol mandates

• Avoiding pregnancy during the vaccination period

• Assessing symptoms of illness

• Ensuring adequate standard of care to control participants– Counselling – pre/post-test, risk reduction,

safer sex– Providing condoms

Page 5: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Care needed to safely complete the trial

• Resuscitation equipment

• Laboratory monitoring of haematologic parameters and other clinical laboratory values of potential interest– Anaemia– Leukopaenia– Alteration of hepatic enzyme tests

Page 6: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Ancillary care in HIV Vaccine trials

• Some questions– What kind of care is needed?– For how long?– By whom?– Whose responsibility?

Page 7: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Ancillary care – some examples

• Hypertension– May be diagnosed incidentally during the conduct

of trial procedures– Treatment is lifelong– Management is multi-modal, i.e. requires attention

to weight, nutrition, exercise, in addition to possible pharmacotherapy

• Facilitating access to services– TOP– Psychosocial support – rape/trauma/DV– Mental illness

• Dental care

Page 8: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

What is “the standard of prevention”?

• HIV counseling and testing– Some protocols may not provide results in ‘real-

time’, depending on the complexity of ruling out vaccine-induced seropositivity

– Impact on testing outside of the trial setting• Other VCTs, blood donation, organ donation, testing for

insurance purposes

– What about partners?• Should we offer CHCT and who is able to do that?

Page 9: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

More “Standard of Prevention”

• Risk reduction counselling– Efforts to standardize that intervention,

such as pilot efforts within DAIDS networks

• Condom promotion vs. provision– Male / Female / both– What other means should be used to

promote condom uptake

Page 10: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

What about additional HIV prevention technologies?

• Male circumcision

• STI treatment – Diagnostics– Directed versus syndromic therapy

• Post-exposure prophylaxis

• Pre-exposure prophylaxis

• Other investigational agents

Page 11: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

What is the Threshold of Evidence for New Prevention Tools?

Page 12: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Cochrane Review of HIV and Circumcision in High Risk Heterosexual Men

Siegfried et al. Lancet Infect Dis 2005

Page 13: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Phambili timelines

17Mar06. MCC submission. GMO submission

8May06. HREC submission

12Sep06. IBC submission

13Oct06. MCC approval

19Oct06. HREC approval24Jan07. First pt enrolled

19 Sep 2007

STEP trial interim resultsJuly 2005 Orange Farm MC trial results

December 2006 Kenyan and Ugandan MC trial results

7March 2007 First Phambili participant provided MC

8Nov06. IBC approval

21Nov06. GMO approval

Page 14: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Location of Studies of Acceptability

Thirteen studies from nine sub-Saharan African countries

Bailey R IAS 2007

Page 15: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Public Sector Circumcisions CHB

Page 16: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Local Expertise

Page 17: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Implementing at the Trial Site / Facilities

Page 18: Care and Prevention in HIV Vaccine Trials: a site perspective Guy de Bruyn Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath.

Circumcision

*129/441 were circumcised at baseline